CD8A and neoplasm: In several animal tumor models, including the ones for PDAC, an inhibitory mAb against B7-H3 demonstrated potent anti-tumor activity evidenced by enhanced CD8 T cell anti-tumor responses, enhanced CD8 T cell infiltration, and suppressed tumor growth [53,58,79].